IDEAYA Biosciences Reports Q4 2025 Results, Awaits Pivotal Uveal Melanoma Trial Data

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2025. The company reported approximately $1.05 billion of cash, cash equivalents, and marketable securities as of December 31, 2025, expected to fund operations into 2030.

The company confirmed that 130 required progression-free survival (PFS) events have been confirmed by blinded independent central review (BICR) in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in first line HLA*A2-negative metastatic uveal melanoma. Topline results, including PFS data, are expected by approximately the last week of March, pending completion of ongoing data collection, cleaning and analysis. The randomized PFS analysis will be based on the intent-to-treat population enrolled in the Phase 2b/3 portion of the trial, which comprises a total of approximately 313 patients randomized 2:1 to the treatment arm versus control.

Topline PFS results, if positive, are anticipated to enable a potential accelerated approval filing in the United States. Full enrollment of 437 patients in OptimUM-02 is complete. Overall survival data from these patients, when available, are expected to support a filing for full approval in first line HLA*A2-negative metastatic uveal melanoma.

Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials across all stages of uveal melanoma by the first half of 2026. The OptimUM-10 neoadjuvant trial is targeting to complete full enrollment of approximately 450 patients across enucleation and plaque brachytherapy cohorts by the first half of 2027. Trial initiation for OptimUM-11 in the adjuvant setting is planned in collaboration with Servier in the second quarter of 2026.

Enrollment of approximately 100 HLA*A2-positive metastatic uveal melanoma patients in single-arm, Phase 2 OptimUM-01 trial of darovasertib in combination with crizotinib is expected to be complete by the second quarter of 2026. Data may support a potential future submission to the U.S. Food and Drug Administration to expand the labeled use of darovasertib and/or a national comprehensive cancer network/compendia listing to enable use of the combination in these patients.

In its antibody-drug conjugate pipeline, IDEAYA enrolled the first patient in a Phase 1 trial for IDE034, a bispecific TOP1 antibody drug conjugate targeting tumors with co-expressed B7H3 and PTK7 antigens. The company received investigational new drug clearance from the U.S. FDA in the fourth quarter of 2025 and achieved first-patient-in in Phase 1 dose escalation trial in the first quarter of 2026. Dosing of the first patient with IDE034 will trigger a $5 million milestone payment from IDEAYA to Biocytogen, pursuant to the Option and License Agreement between the companies.

For IDE849, a DLL3 TOP1 ADC, the company is targeting to provide a preliminary clinical data update from IDEAYA-sponsored global Phase 1 trial and initiate a monotherapy registrational study in the second line/refractory setting of small cell lung cancer and/or neuroendocrine carcinomas by the end of 2026.

The company is also planning initiation of clinical combination studies with IDE161 (PARG) and IDE849 in small cell lung cancer, neuroendocrine carcinomas and other DLL3-overexpressing solid tumors in the second quarter of 2026. For IDE397 (MAT2A), the company is planning to provide updated data from Phase 1/2 combination trial with Trodelvy in MTAP-deleted urothelial cancer at a medical conference in 2026.

IDEAYA Biosciences is headquartered in South San Francisco, California, and has a market capitalization of $3.08 billion. The company's stock is currently trading at $35.08, within a 52-week range of $14.50 to $37.86. The stock is trading above its 50-day moving average of $33.96 and significantly above its 200-day moving average of $28.41. The company reported revenue growth of 55.40% with a revenue base of $218.71 million.

Darovasertib is an oral PKC inhibitor being evaluated as a treatment for uveal melanoma and other ocular cancers driven by GNAQ/11 mutations. The company maintains strategic alliances with industry partners including GlaxoSmithKline, Pfizer, and Novartis to support its research and development capabilities.